VasoSome Vascular

VasoSome Vascular is a private vascular biotechnology company focused on developing an exosome-based therapy for abdominal and other aortic aneurysms. The company was launched in 2023 by Therapeutic Solutions International as a subsidiary/spin-off built around patent-pending stem cell-derived exosome technology. Its lead effort is aimed at stabilizing or reversing aneurysm growth in patients for whom current treatment options are largely limited to open surgical or endovascular repair. Public descriptions indicate the program was in IND-enabling development with plans for an early Phase 1/2 study, but there is no clear evidence of an active registered clinical-stage program as of April 9, 2026. The company appears to remain an early-stage, preclinical regenerative medicine venture centered on vascular disease.